Spironolactone is an antagonist of NRG1‐ERBB4 signaling and schizophrenia‐relevant endophenotypes in mice

Enhanced NRG1‐ERBB4 signaling is a risk pathway in schizophrenia, and corresponding mouse models display several endophenotypes of the disease. Nonetheless, pathway‐directed treatment strategies with clinically applicable compounds have not been identified. Here, we applied a cell‐based assay using...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehr, Michael C, Hinrichs, Wilko, Brzózka, Magdalena M, Unterbarnscheidt, Tilmann, Herholt, Alexander, Wintgens, Jan P, Papiol, Sergi, Soto‐Bernardini, Maria Clara, Kravchenko, Mykola, Zhang, Mingyue, Nave, Klaus‐Armin, Wichert, Sven P, Falkai, Peter, Zhang, Weiqi, Schwab, Markus H, Rossner, Moritz J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653977/
https://www.ncbi.nlm.nih.gov/pubmed/28743784
http://dx.doi.org/10.15252/emmm.201707691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653977/
https://www.ncbi.nlm.nih.gov/pubmed/28743784
http://dx.doi.org/10.15252/emmm.201707691

Ejemplares similares